What is the role of novel taxanes in non-small-cell lung cancer?
The taxanes are among the most active cytotoxic agents in oncology and are widely used in adjuvant and advanced treatment settings in multiple tumor types. Paclitaxel and docetaxel are standard therapies in advanced non-small-cell lung cancer (NSCLC) and are increasingly used in earlier treatment settings. The taxanes are generally well tolerated but can be associated with severe, irreversible (and rarely life-threatening) toxicity. Premedication and special infusion sets are necessary to reduce the risk of hypersensitivity reactions. Newer taxanes are in development designed to improve the therapeutic index and ease of administration. Several agents have completed phase I/II clinical trials and are in phase III testing. Many other novel taxanes are at earlier stages of development and appear promising as single agents and in combination regimens. Safer and more effective taxanes could replace paclitaxel and docetaxel as standard treatments in NSCLC.
Sarah Cannon Research Institute, Nashville, TN 37203, USA. dspigel@tnonc.com
David R
DR
Spigel
F Anthony
FA
Greco
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003432:Cross-Linking Reagents / Q000008:administration & dosage / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D003432:Cross-Linking Reagents; D043823:Taxoids; D000077143:Docetaxel; C426424:7-methylthiomethylpaclitaxel; D016190:Carboplatin; D017239:Paclitaxel